文献速递脊柱关节炎

中轴型脊柱关节炎的当前标准治疗与未满足需求

The current standard of care and the unmet needs for axial spondyloarthritis.
PubMed 文献 · Rheumatology (Oxford) · 2018-01-01

本文探讨中轴型脊柱关节炎(axSpA)现有治疗(物理治疗、NSAIDs、csDMARDs、TNF抑制剂)的获益与局限,并简述抗IL-17治疗(如苏金单抗)作为一线生物制剂替代或TNF抑制剂应答不足后二线选择的潜在价值。

要点

  • 运动项目改善AS患者健康相关生活质量,水疗改善疾病活动度和功能参数。
  • NSAIDs可使70-80%患者症状显著缓解,但预防放射学进展的作用尚不明确。
  • csDMARDs仅限外周关节炎,轴向病变证据不足;TNF抑制剂降低疾病活动度但并非所有患者应答一致。

核心结论

  • 现有axSpA治疗各有局限,抗IL-17治疗可能成为一线生物制剂替代或TNF抑制剂应答不足后的二线选择。

研究设计与样本

  • 本文为综述,探讨axSpA已有治疗(物理治疗、NSAIDs、csDMARDs、TNF抑制剂)的获益与局限,并简要讨论抗IL-17治疗的 emerging 作用。

主要发现

  • 运动项目改善AS患者健康相关生活质量,水疗改善疾病活动度和功能参数。
  • NSAIDs可使70-80%患者症状显著缓解,并通过减轻疼痛和僵硬增强物理治疗效果,但预防放射学进展的作用尚不明确。
  • csDMARDs仅限用于外周关节炎,轴向病变使用证据不足。
  • TNF抑制剂降低axSpA疾病活动度,但并非所有患者应答一致,因此需要其他治疗选择。

关键数值与推荐

  • NSAIDs可使70-80%患者症状显著缓解。
  • csDMARDs仅限外周关节炎,轴向病变证据不足。
  • 抗IL-17治疗可作为一线生物制剂DMARD的替代或TNF抑制剂应答不足后的二线治疗。

临床怎么用

  • axSpA治疗可选用物理治疗、NSAIDs、csDMARDs(限外周关节炎)和TNF抑制剂,并考虑抗IL-17治疗作为替代或后续选择。

局限性

  • 本文为综述,未报告系统检索范围;NSAIDs预防放射学进展的作用尚不明确;csDMARDs用于轴向病变证据不足。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The aim of this article is to explore the benefits and limitations of the established treatments for axial SpA (axSpA), including physiotherapy, NSAIDs, conventional synthetic DMARDs and biologic DMARDs such as TNF inhibitors (TNFis). It also briefly discusses the emerging role of anti-IL-17 therapy, which could be used as a valuable alternative to first-line biologic DMARD treatment or as a second-line treatment for patients who are inadequate responders to TNFi therapy, as evidenced by various studies. Exercise programmes improve health-related quality of life and hydrotherapy improves disease activity and functional parameters in AS. NSAIDs have been proven to substantially relieve symptoms in 70-80% of patients and enhance physiotherapy by reducing pain and stiffness. The role of NSAIDs in preventing radiographic progression remains unclear. The use of conventional synthetic DMARDs (csDMARDs) is limited to peripheral arthritis; there is insufficient evidence to support the use of csDMARDs for axial disease. TNFi therapy reduces the disease activity of axSpA, however, as not all patients respond to treatment in the same way, it is good to have other therapeutic options available. Finally, this article explores the potential for IL-17 inhibition in AS and introduces clinical data for secukinumab, a fully human monoclonal antibody targeting IL-17A.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Noureldin B, Barkham N. The current standard of care and the unmet needs for axial spondyloarthritis. Rheumatology (Oxford). 2018. PMID: 30445485. doi:10.1093/rheumatology/key217

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。